Ephepoetin Alpha

重组人促红素-HyFc融合蛋白

Report date: 2026/05/23 20:00:57

Base Information

Drug NameEphepoetin Alpha
Drug Alias NameEfepoetin alfaErythropoietin biobetterLong-acting EPOHyPoietinRecombinant erythropoietin long-acting +[12] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemiaRenal Insufficiency, ChronicRenal Insufficiency
Global Approved IndicationsAnemia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndonesia
Original Approved Date2023/10/23
Country/TerritoryCzechiaArmeniaBulgaria +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGannex Pharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGannex Pharma Co LtdPt Kalbe Genexine BiologicsShanghai Kaimao Bio-Pharmaceutical Co Ltd
Inactive CompaniesGC Biopharma Corp
Active IndicationsAnemia
Inactive IndicationsRenal Insufficiency, ChronicRenal Insufficiency

Other Information

ATC CodeN/A
Related LinksN/A